RECODE · 연구동향생성일 2026-10-31

연구동향

기준 논문: Combination of clinical and neuropsychologic information as a better predictor of the progression to Alzheimer disease in questionable dementia individuals

Am J Geriatr Psychiatry 14(2):130-138 · 2006 · PMID 16473977

검색 방법

이 논문의 제목과 주제어를 바탕으로 이 논문이 속한 연구 분야를 묻는 질문을 만들어 ReviewFast에 넣어 2026-10-31에 검색했습니다. ReviewFast가 PubMed를 검색하고, AI 모델(Jev)이 제목과 초록을 읽어 질문과의 관련도를 매긴 뒤 주제별로 묶었습니다.

40,729편 검색→1,970편 판독→213편 선별 (관련도 0.5 이상)

질문과 PubMed 검색식 보기질문: Clinical and neuropsychological predictors of progression from questionable dementia or mild cognitive impairment to Alzheimer disease Clinical and neuropsychological predictors of progression from questionable dementia or mild cognitive impairment to Alzheimer disease

출판 연도

2025: 2편220252026: 210편2102027: 1편12027

선별된 213편의 출판 연도. 검색일(2026-10-31) 기준이며, 그 이후 논문은 들어 있지 않습니다.

주제별 논문

주제 이름은 ReviewFast가 초록의 단어로 자동으로 붙인 것입니다. 왼쪽 숫자는 관련도(0–1)입니다. RECODE 는 우리 연구팀 논문입니다.

01plasma · biomarkers67편

  1. 0.93

    A cerebrospinal fluid blood-brain barrier dysfunction score is associated with progression from mild cognitive impairment to Alzheimer's disease

    Yang J · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026

  2. 0.91

    A Three-Item Functional Screen for Multimodal Prognostic Triage in Mild Cognitive Impairment: Benchmarking Against Entorhinal Tau PET and Plasma p-tau217

    Lafille J, Provenzano F · medRxiv : the preprint server for health sciences · 2026

  3. 0.91

    Serum beta-synuclein predicts dementia conversion and mortality beyond amyloid-beta and phospho-tau

    Oberstein TJ, Schwarz J, Rudtke L et al. · Brain : a journal of neurology · 2026

  4. 0.90

    Development and External Validation of a Plasma p-tau217-Based Model for MCI-to-Dementia Progression

    Du M, Roy I, Chu B et al. · medRxiv : the preprint server for health sciences · 2026

  5. 0.90

    Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort

    Cottez RJ, Peyrot C, Denis HL et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  6. 0.90

    Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old

    Ceriello C, Torres OH, Rubio-Guerra S et al. · Neurology · 2026

  7. 0.90

    A leakage-controlled multi-compartment benchmark of fluid biomarkers for predicting mild cognitive impairment to Alzheimer's disease conversion: plasma, CSF, and high-plex omics in a single cohort

    Cangas Caiza IJ · Research square · 2026

  8. 0.88

    Plasma myeloperoxidase predicts cognitive decline in mild cognitive impairment: a multicenter longitudinal cohort study

    Sun W, Shan A, Wang P et al. · The journals of gerontology. Series A, Biological sciences and medical sciences · 2026

  9. 0.88

    Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progression

    Delaby C, Schraen-Maschke S, Paquet C et al. · Molecular psychiatry · 2026

  10. 0.87

    Paired CSF-Plasma Analyte Signal Contrasts Across Alzheimer's Disease Clinical Stages and MCI-to-Dementia Conversion

    Deng Y, Chen D, Yin H et al. · Biomedicines · 2026

  11. 0.87

    Neuroimaging Epicenters as Vulnerable Nodes in Plasma p-tau217/Abeta42-Positive Alzheimer's Disease

    Li Q, Liu Y, Chen Q et al. · Research (Washington, D.C.) · 2026

  12. 0.87

    Hippocampal asymmetry captures non-amyloid-related risk of memory decline and clinical progression

    Ghanbarian E, Khorsand B, Zheng L et al. · The journal of prevention of Alzheimer's disease · 2026

  13. 0.87

    Clinical utility of combined amyloid biomarkers in early cognitive impairment

    Chiang PT, Cheng SY, Hsueh SJ et al. · Journal of Alzheimer's disease : JAD · 2026

  14. 0.86

    CSF APOE Secondary Glycosylation Predicts Cognitive Decline in Mild Cognitive Impairment

    Jiao Y, Du C, Ding Y et al. · Biomedicines · 2026

  15. 0.85

    APOE epsilon4-specific associations between agitation, cerebrospinal fluid biomarkers, and cognitive decline in cognitively impaired patients

    Du X, Wang Y, Zhao J et al. · Journal of Alzheimer's disease : JAD · 2026

  16. 0.84

    Neutrophil-to-lymphocyte ratio predicts early cognitive decline associated with tau pathology in Alzheimer's disease: a longitudinal study of the ADNI cohort

    Wang X, Liu X, Wang Z et al. · Frontiers in aging neuroscience · 2026

  17. 0.84

    Combining plasma biomarkers and cognitive challenge tests enhances prediction of functional trajectories of decline among older adults with cognitive impairment

    Diane Zheng D, Curiel Cid RE, Ortega A et al. · Journal of Alzheimer's disease : JAD · 2026

  18. 0.83

    Symptom-Guided Blood Biomarker Testing for Alzheimer's Disease

    Howe MD, Zide BS, Hayes K et al. · Dementia and geriatric cognitive disorders · 2026

  19. 0.83

    Associations between cerebrospinal fluid biomarkers related to endothelial dysfunction and Alzheimer's disease

    Zhu YK, Zhu QJ, Wang LY et al. · Frontiers in aging neuroscience · 2026

  20. 0.81

    Baseline cerebrospinal fluid complement balance is associated with longitudinal memory decline in relation to plasma p‑tau181 levels in mild cognitive impairment

    Ye Z, Zhang Q, Zhang B et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  21. 0.81

    Interactive Effects of Plasma Alzheimer Disease Biomarkers and White Matter Hyperintensities on Cognitive Decline and Clinical Progression in Nondemented Adults

    Yang J, Zhao X, Liu Y et al. · Journal of the American Heart Association · 2026

  22. 0.81

    Alzheimer's blood-based biomarkers, incident dementia, and interactions with age, APOE status, and hormone therapy

    Mielke MM, Gaussoin SA, Casanova R et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  23. 0.80

    Cerebrospinal fluid glial cell line-derived neurotrophic factor levels interact with APOE epsilon4 genotype to influence cognitive decline in older adults without dementia

    Wang S, Zou S · Journal of Alzheimer's disease : JAD · 2026

  24. 0.78

    Biomarker affliction classes contribute additively to observed dementia severity and prospective conversion risk

    Royall DR, Palmer RF · Journal of Alzheimer's disease : JAD · 2026

  25. 0.78

    Higher baseline CSF cortisol is associated with adverse 24-month tau-related, neuroimaging, and cognitive outcomes across the Alzheimer's disease continuum

    Alreshidi NF, Abdullah Alghamdi A, Almasoudi KS et al. · European geriatric medicine · 2026

  26. 0.78

    Association Between Plasma N-Terminal Tau, Cognitive Decline, and Neurodegeneration in the ADNI Cohort

    Rao Y, Liu L, Ostaszewski BL et al. · Neurology · 2026

  27. 0.77

    Associations of peripheral inflammation with hippocampal atrophy in Alzheimer's disease

    Xie H, Li Y, Gan R et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2026

  28. 0.77

    Diagnostic and Prognostic Utility of Plasma p-tau217 for Alzheimer's Disease in Chinese Elderly: Insights From the SILCODE Study With a Derived Threshold

    Li R, Yang J, Chai W et al. · European journal of neurology · 2026

  29. 0.75

    Scalable markers for early cognitive decline: Plasma p-tau217, subjective cognitive concerns, and digital testing: Results from the A4/LEARN studies

    Khorsand B, Teichrow D, Ghanbarian E et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  30. 0.75

    miR-214-3p and NCKAP1: A microglial functional dimension of Alzheimer's progression

    Noh MY, Moon Y, Kang S et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  31. 0.74

    CSF Levels of Baseline VCAM-1 and ICAM-1 Are Associated with Tau Pathology in Patients Demonstrating Cognitive Impairment

    Aljuhani M, Ashraf A, Alqarni A et al. · Neurology international · 2026

  32. 0.74

    Associations among sleep quality, cognitive decline, and Alzheimer's disease pathology in older adults: A longitudinal study

    Shihadeh L, Rosselli M, Conniff J et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  33. 0.74

    Blood biomarkers predict conversion from cognitively stable to mild cognitive impairment or Alzheimer's disease in Down syndrome at 16-month follow-up in ABC-DS

    Zhang F, Petersen M, Mapstone M et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  34. 0.73

    Integration of blood-based biomarkers and genomic variants identifies individuals with mild cognitive impairment who benefit from multidomain intervention

    Kimura T, Nakamura A, Sugimoto T et al. · Alzheimer's & dementia (New York, N. Y.) · 2026

  35. 0.72

    White matter (18)F-florbetapir retention predicts cognitive decline and treatment response in Alzheimer's disease

    Lin H, Zhang Y, Ni R et al. · Alzheimer's research & therapy · 2026

  36. 0.72

    Longitudinal plasma p-tau217 as a marker for tracking progression and predicting cognitive decline in Alzheimer's disease

    Ahn J, Yun J, Weiner MW et al. · Alzheimer's research & therapy · 2026

  37. 0.71

    Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease

    Vanderlip CR, Stark CEL · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  38. 0.69

    Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience

    Fonseca LM, Lila E, Shojaie A et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  39. 0.69

    Clinical and Biologic Characterization of a 3-Level Centiloid-Based Classification of Amyloid PET

    Mathoux G, Boccalini C, Peretti DE et al. · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026

  40. 0.68

    Association of plasma biomarkers with longitudinal change in age- and Alzheimer's disease-related brain atrophy patterns

    Bilgel M, Shah I, Cooper J et al. · medRxiv : the preprint server for health sciences · 2026

  41. 0.67

    Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment

    Buckley RF, Townsend DL, Birkenbihl CJ et al. · JAMA · 2026

  42. 0.66

    Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer's disease

    Labrador-Espinosa MA, Franzmeier N, Karagianni S et al. · Alzheimer's research & therapy · 2026

  43. 0.65

    Correlation analysis of positive Alzheimer's disease plasma biological markers with plasma immune cell and clinical characteristics in mild cognitive impairment patients in China

    Wang L, Zhang P, Gao S et al. · BMC immunology · 2026

  44. 0.62

    Multimodal Integration of Gait Dysfunction, Amyloid PET, and Plasma Biomarkers for Differentiating Etiological Subtypes in Mild Cognitive Impairment

    Wu J, Tang F, Lv X et al. · CNS neuroscience & therapeutics · 2026

  45. 0.62

    Glial and Vascular Plasma Biomarkers Across the Alzheimer's Disease Continuum: An ADNI-Based Longitudinal Study

    Jahanbin K · FASEB bioAdvances · 2026

  46. 0.60

    Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

    Lopez-Martos D, Suarez-Calvet M, Salvado G et al. · Neurobiology of aging · 2026

  47. 0.60

    Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies

    Xu Y, Gunasekaran TI, Gu Y et al. · The Lancet. Neurology · 2026

  48. 0.60

    CSF and plasma lipid profiling predicts risk of cognitive impairment in cognitively unimpaired older adults

    Kanekiyo T, White LJ, Ye H et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  49. 0.60

    Relative importance of blood-based biomarkers for Alzheimer's disease-specific neurodegeneration and cognitive decline

    Kim KY, Ham H, Yoon EJ et al. · The journal of prevention of Alzheimer's disease · 2026

  50. 0.59

    Plasma p-tau217 best captures early longitudinal cognitive changes in subjective cognitive decline compared with p-tau181 and NfL

    Giacomucci G, Pieri A, Bagnoli S et al. · Journal of neurology · 2026

  51. 0.57

    APOE epsilon4 accelerates plasma p-tau217 trajectory: a Bayesian joint longitudinal analysis of ADNI

    Chu KY · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026

  52. 0.57

    Mild behavioral impairment-apathy and Alzheimer's disease plasma phosphorylated tau biomarker levels

    Vellone D, Leon R, Goodarzi Z et al. · Journal of Alzheimer's disease : JAD · 2026

  53. 0.57

    Mild Amyloid Burden in the Brains of Cognitively Unimpaired Individuals is Associated with Long-Term Cognitive Impairment

    Xiong C, Luo J, Hartz S et al. · Annals of neurology · 2026

  54. 0.56

    Dual decline in gait and cognition as a high-risk clinical phenotype: differential associations with cerebral amyloid-beta deposition and the apolipoprotein E epsilon4 allele and implications for integrated assessment

    Ren C, Zhu J, Huang L et al. · Frontiers in aging neuroscience · 2026

  55. 0.56

    Synergistic association of insomnia and anxiety with cognitive impairment and dementia in older adults

    Chen Y, Wang Q, Li L et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  56. 0.56

    Blood Biomarkers of Alzheimer Disease and Rates of Global and Domain-Specific Cognitive Decline

    Laukka EJ, Ekstrom I, Valletta M et al. · JAMA network open · 2026

  57. 0.55

    Metabolism of the antioxidant micronutrient ergothioneine as a plasma biomarker of cognitive resilience in older people with Alzheimer's disease amyloid pathology

    Chong JR, Cheah IK, Tang RM et al. · Free radical biology & medicine · 2026

  58. 0.55

    The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease staging

    Verberk IMW, de Koning LA, Coomans EM et al. · Alzheimer's research & therapy · 2026

  59. 0.54

    Naturalistic Driving Engineered Trajectories Forecast Future Cognitive Decline

    Pal S, Brown DC, Chen C et al. · The journals of gerontology. Series B, Psychological sciences and social sciences · 2026

  60. 0.52

    Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease

    Salvado G, Horie K, Barthelemy NR et al. · JAMA neurology · 2026

  61. 0.52

    Cerebrospinal fluid homocysteine, but not plasma homocysteine, is associated with markers of tau pathology and neurodegeneration

    Lee JH, Won GH, Lee SI et al. · Journal of Alzheimer's disease : JAD · 2026

  62. 0.51

    Astrocyte reactivity modifies the effects of locus coeruleus norepinephrine-related dysfunction on tau and its impact on cognition

    Prokopiou PC, Van Egroo M, Riphagen JM et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  63. 0.51

    Changes in Plasma Amyloid beta 1-42 Peptide and Total Tau Protein from Normal Cognition to Sever-Stage Alzheimer's Disease Using an Immunomagnetic Reduction Assay

    Yang SY, Liu HC, Chiu MJ et al. · ACS omega · 2026

  64. 0.51

    Mapping sex-specific associations of adiposity with age-related cognitive decline and multimodal Alzheimer's pathology

    Zhang J, Liu D, Yang Y et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  65. 0.50

    CogStrat: web-based tools for predicting incident cognitive impairment in cognitively normal older adults

    Jimenez-Huete A, Ulloa Bravo JS, Martin-Bastida A et al. · Journal of neural transmission (Vienna, Austria : 1996) · 2026

  66. 0.50

    APOE Genotype Modifies the Predictive Performance of Plasma Biomarkers for Amyloid Plaque Burden in Subjective Cognitive Decline

    Lee HJ, Yoon B, Hong YJ et al. · Journal of Korean medical science · 2026

  67. 0.50

    Elevated endogenous glucagon-like peptide-1 as a novel Alzheimer's disease biomarker associated with neuroinflammation and Abeta pathology

    Li J, Ji C, Wang J et al. · General psychiatry · 2026

02imaging · regions48편

  1. 0.92

    Individualized cholinergic pathway degeneration in Alzheimer's disease characterized by normative modeling

    Feng S, Zhuang H, Xu C et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2026

  2. 0.91

    Neurophysiological Differentiation of Conversion to Alzheimer's Disease: Longitudinal Changes in P300 Amplitude as an Indicator of Mild Cognitive Impairment Progression

    Ozbek Y, Yener GG · Brain and behavior · 2026

  3. 0.90

    Structural MRI and mild behavioral impairment as complementary predictors of conversion from amnestic MCI to Alzheimer's disease

    Tomyshev A, Cherkasov N, Panikratova Y et al. · Neuroscience · 2026

  4. 0.88

    Regional amyloid PET asymmetry and long-term clinical trajectory in mild cognitive impairment

    Lee Y, Kang S, Kim YS et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2026

  5. 0.87

    EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease: An MRI-Based Prognostic Biomarker

    Paranhos T, Katsumi Y, Brickhouse MJ et al. · Neurology · 2026

  6. 0.87

    Progression from mild cognitive impairment to dementia in Alzheimer's disease: Whole cortex voxelwise functional connectivity analysis with multivariate distance matrix regression

    Ferreira LK, Westman E, Wahlund LO et al. · Journal of Alzheimer's disease : JAD · 2026

  7. 0.87

    Circulating Homocysteine and Choroid Plexus Volume Across the Alzheimer's Disease Continuum: Cross-Sectional and Progression-Related Associations

    Feng C, Zhang T, Liu X et al. · Biology · 2026

  8. 0.85

    Sex-specific brain reserve and progression from mild cognitive impairment to Alzheimer's disease dementia

    Liu X, de Boer SCM, Tartaglia MC · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  9. 0.84

    Structural compression and entorhinal vulnerability: Linking tentorial adjacency to tau burden and dementia progression

    Zhang L, Franceschi AM, Crary JF et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  10. 0.84

    Utility of biomarkers in prediction of future cognition in Alzheimer's disease continuum changes over time

    Ramezannezhad E, Dehghani M · Journal of Alzheimer's disease : JAD · 2026

  11. 0.81

    Atrophy of specific amygdala subregion precedes the conversion from mild cognitive impairment with neuropsychiatric symptoms to dementia

    Pan C, Ma J, Yuan X et al. · International psychogeriatrics · 2026

  12. 0.80

    Metabolic context modulates neuroinflammation: Type 2 diabetes mellitus moderates the association of interleukin-8 with amyloid pathology and cognitive decline in mild cognitive impairment

    Kim EW · Journal of Alzheimer's disease : JAD · 2026

  13. 0.80

    Change in brain glucose metabolism and cognition in amnestic MCI patients in relation to amyloid accumulation: A 3-year follow-up study

    Rauhala E, Johansson J, Karrasch M et al. · Aging brain · 2026

  14. 0.74

    Cortico-white Matter Functional Coupling as a Biomarker of Alzheimer's Disease Progression and rTMS Therapeutic Efficacy

    Liu Y, Zhang Y, Zheng W et al. · Current neuropharmacology · 2026

  15. 0.73

    Brain tau network derived biomarker improves the diagnostic accuracy of Alzheimer's disease

    Pan T, Zhou Q, Li P et al. · Brain research bulletin · 2026

  16. 0.72

    Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease

    Li Y, Wang D, Zhou R et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  17. 0.72

    Hippocampal-cortical structural networks in the progression of cognitive impairment: A source-based morphometry analysis in individuals with subjective cognitive decline, mild cognitive impairment and Alzheimer's disease

    Serra L, Mancini M, Bonarota S et al. · Neurobiology of aging · 2026

  18. 0.71

    The role of glymphatic-related structural and functional imaging biomarkers in the pathological progression of Alzheimer's disease: a multimodal imaging-based study

    Tan M, Lan X, Anayiti X et al. · Quantitative imaging in medicine and surgery · 2026

  19. 0.71

    Alterations in topological and dynamical parameters correlate with disease biomarkers and neuropsychological scores in prodromic stages of dementia

    Monteverdi A, Cotta Ramusino M, Conca F et al. · Scientific reports · 2026

  20. 0.70

    Virtual brain and electroencephalography explain the variance of memory alterations in mild cognitive impairment

    Monteverdi A, Cotta Ramusino M, Conca F et al. · Alzheimer's research & therapy · 2026

  21. 0.70

    APOE4-specific glymphatic effects on clinical progression in the Alzheimer's Disease Neuroimaging Initiative with pathological correlates in the A4 study

    Saadawy M, Majeed M, Saadawy E · Journal of Alzheimer's disease : JAD · 2026

  22. 0.69

    Network-level functional connectivity is associated with longitudinal tau accumulation and amyloid-dependent cognitive decline in preclinical Alzheimer's disease

    Javanray M, Gallego-Rudolf J, Yakoub Y et al. · Research square · 2026

  23. 0.69

    Change in Amyloid-beta Deposition and Diffusion Tensor Image Analysis along the Perivascular Space Index in Incident Neurodegenerative Disease

    Lim S, Lee Y, Yun CS et al. · Annals of neurology · 2026

  24. 0.67

    Stage-specific hippocampal network degeneration links amyloid-cognition relationships: Right subiculum as structural substrate for memory maintenance and biomarker in amyloid-positive mild cognitive impairment

    Wang Z, Huang L, Guan Y et al. · NeuroImage · 2026

  25. 0.67

    Amygdala subregional atrophy across ATN-defined Mild Cognitive Impairment subgroups

    Yuan Q, Xue C, Qi W et al. · Frontiers in neuroscience · 2026

  26. 0.66

    APOE epsilon4-related structural vulnerability in mild cognitive impairment: a subsystem-based analysis of the default mode network

    Yang X, Lyu J, Wang J et al. · Research square · 2026

  27. 0.66

    Enlarged perivascular spaces in subcortical white matter are linked to amyloid-tau depositions and cognitive decline: Data from a memory clinic in Thailand

    Booncharoen K, Thanapornsangsuth P, Pongpitakmetha T et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2026

  28. 0.66

    Periventricular and Perivascular-Space Diffusion MRI Measures, Amyloid Abnormality, and Executive Decline in the Alzheimer's Disease Continuum: A Longitudinal Study

    Chen C, Gu J, Hu Q et al. · Journal of magnetic resonance imaging : JMRI · 2026

  29. 0.64

    Mechanomarker-informed identification of Alzheimer's disease based on lateral ventricular deformation

    Cunniff L, Weickenmeier J · Brain research bulletin · 2026

  30. 0.63

    Serum Lipoprotein Subclasses as Predictors of Tensor-Based Morphometry Atrophy in the Alzheimer Disease Continuum: A Brief Report

    Khosravi F, Ashrafi M, Abroushan D et al. · Alzheimer disease and associated disorders · 2026

  31. 0.63

    Disentangling global atrophy burden from local structural patterns reveals clinically relevant heterogeneity in mild cognitive impairment

    Yang X, Lyu J, Wang J et al. · BMC neuroscience · 2026

  32. 0.63

    Determining the metabolic profile measured using ultra-high pressure liquid chromatography associated with Beta Amyloid burden in the brain in individuals with mild cognitive impairment

    Falahati M, Ramezannejad E, Vaez-Gharamaleki Y et al. · Research square · 2026

  33. 0.60

    Decoupling of local activity and interhemispheric connectivity in late mild cognitive impairment: A resting-state functional magnetic resonance imaging study

    Jin Z · Neuropsychology · 2026

  34. 0.58

    Topography of Juxtaventricular white matter hyperintensities and cognitive associations in Alzheimer's disease: a dual-cohort study

    Bao YW, Ji YQ, Wang LN et al. · European radiology experimental · 2026

  35. 0.57

    Stage-dependent relationship between sleep duration and cortical tau deposition in cognitively impaired individuals: A cross-sectional study

    Zheng Y, Kang L, Yang X et al. · Journal of Alzheimer's disease : JAD · 2026

  36. 0.57

    DTI-ALPS associations with regional amyloid deposition and glucose metabolism in mild cognitive impairment and Alzheimer's disease

    Yi C, Chen W, Shi X et al. · Journal of neuroradiology = Journal de neuroradiologie · 2026

  37. 0.56

    Sleep-like slow waves during resting-state: A promising EEG biomarker of amyloid and neurodegeneration in preclinical Alzheimer's disease

    Champetier P, Albero C, Raposo Pereira F et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  38. 0.56

    Spatiotemporal atrophy subtypes in Alzheimer's disease: Neurodegenerative-vascular associations and potential prognostic value

    Mao C, Qiu Y, Li B et al. · NeuroImage · 2026

  39. 0.56

    Atrophy in preclinical Alzheimer's disease maps to a network that predicts longitudinal decline

    Lee S, Baratono SR, Ha J et al. · Molecular psychiatry · 2026

  40. 0.53

    Cognitive vergence and pupillary responses as functional oculomotor signatures to differentiate AT(N) biological profiles in older adults with mild cognitive impairment

    Martinez-Flores R, Martin-Sobrino I, Falgas N et al. · GeroScience · 2026

  41. 0.53

    From function to structure: Cortical thickness correlates of olfactory dysfunction across cognitively normal, mild cognitive impairment and Parkinson's disease

    Giriprakash PP, Caldwell JZK, Doty RL et al. · Journal of the neurological sciences · 2026

  42. 0.53

    Modular brain networks shape amyloid-driven tau spread and cognitive decline

    Hirsch F, Frontzkowski L, Steward A et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  43. 0.52

    Five-year change in brain metabolism across the spectrum of cognitive impairment in older adults: a quantitative MRI study

    Wu J, Oishi K, Soldan A et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  44. 0.52

    Multimodal Imaging of Tau Pathology and Network Connectivity Dynamics Across the Alzheimer's Continuum: A Pilot Study Using Second-Generation Tracer [(18)F]MK6240

    Piao S, Wang J, He K et al. · Academic radiology · 2026

  45. 0.51

    A longitudinal investigation of locus coeruleus norepinephrine system integrity and cognitive performance across the Alzheimer's spectrum

    Sibahi A, Hosseini SA, Rahmouni N et al. · Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026

  46. 0.51

    Precuneus amyloid-beta deposition involving the association of irritability and cognitive decline: A multi-cohort longitudinal study

    Liu Y, Qiu Q, Yue L et al. · Journal of Alzheimer's disease : JAD · 2026

  47. 0.51

    Metabolic profile association with white matter hyperintensity in patients with mild cognitive impairment

    Ariaei A, Zamiri R, Ghasemi A et al. · IBRO neuroscience reports · 2026

  48. 0.50

    Vascular brain injury modifies the relationship between sleep duration, cognition, and white matter hyperintensity burden in the Alzheimer's disease continuum

    Lahlou S, Ismail Z, Smith EE et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

03learning · model42편

  1. 0.95

    Comparative Value of Cognitive and Functional Assessments for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer's Disease: An ADNI Cohort Study

    Choe S · medRxiv : the preprint server for health sciences · 2026

  2. 0.94

    Standardized Comparison of Clinical, Cognitive, Genetic, Neuroimaging, and Fluid Biomarkers for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer's Disease

    Choe S · medRxiv : the preprint server for health sciences · 2026

  3. 0.92

    Modelling the risk of conversion from mild cognitive impairment to Alzheimer's disease using machine learning

    Mouiha A, Taiebine M, El Hilaly J · Journal of education and health promotion · 2026

  4. 0.90

    A dual space MRI radiomic network signature for risk stratification and subtyping of mild cognitive impairment

    Xiong D, Liu M, Xie J et al. · iScience · 2026

  5. 0.90

    Predicting MCI-to-Alzheimer's Conversion: A Systematic Benchmark of Classical, Machine Learning, and Deep Survival Models

    Santa NA, Daza-Santacoloma G, Serna WS · Diagnostics (Basel, Switzerland) · 2026

  6. 0.89

    Scalable CT-based prognostic modeling of dementia conversion in mild cognitive impairment

    Park S, Ahn J, Na DL et al. · Scientific reports · 2026

  7. 0.88

    Forecasting Alzheimer's disease progression using non-imaging clinical features and XGBoost

    Gautier A, Zheng L, Schreurs BG · medRxiv : the preprint server for health sciences · 2026

  8. 0.87

    A score based on MRI imaging variables can predict time to moderate progression in mild cognitive impairment: Multimodal data integration study

    Jodlowska-Siewert E, Liu L, Yang K et al. · Journal of Alzheimer's disease : JAD · 2026

  9. 0.86

    Decoding Choroid Plexus Pathology in Alzheimer's Disease: A Longitudinal Radiomics Approach for Prodromal Identification and Risk Stratification

    Yin F, Wang X, Chen X et al. · CNS neuroscience & therapeutics · 2026

  10. 0.85

    Detecting Mild Cognitive Impairment to Alzheimer's Disease Progression by fMRI Using Convolutional Neural Network and Long-short Term Memory

    Ghafoori S, Shalbaf A · Basic and clinical neuroscience · 2025

  11. 0.84

    Stratifying heterogeneity in mild cognitive impairment: A multimodal subtype and stage inference approach

    Rodolfo CC, Vinicius SR, Francesca B et al. · Neurobiology of aging · 2026

  12. 0.83

    Shape-Based Partially Linear Single-Index Cox Model for Alzheimer's Disease Conversion

    Li X, Zhou Q, Ding S et al. · Statistics in medicine · 2026

  13. 0.83

    Systematic Modality Ablation of Multimodal Machine Learning for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer's Disease

    Choe S · medRxiv : the preprint server for health sciences · 2026

  14. 0.82

    Predicting the Conversion From Mild Cognitive Impairment to Alzheimer's Disease Using Graph Frequency Bands and Functional Connectivity-based Features

    Zamani J, Talesh Jafadideh A · Basic and clinical neuroscience · 2025

  15. 0.82

    A multimodal machine learning model integrating plasma biomarkers and MRI metrics for non-invasive prediction of amyloid-beta pathology in mild cognitive impairment

    Fang Q, Guo Y, Chen L et al. · Journal of Alzheimer's disease : JAD · 2026

  16. 0.81

    Multimodal prediction of MCI-to-dementia conversion over a two-year window

    Simkhada B, Liang TY, Cui X et al. · GeroScience · 2026

  17. 0.78

    No evidence that serum metabolite slopes improve held-out prediction of clinical progression in the Alzheimer's disease neuroimaging initiative

    Warrick T, Misra M, Kataria S et al. · Frontiers in aging neuroscience · 2026

  18. 0.76

    Retinal neurovascular coupling dysfunction and plasma metabolomic features as biomarkers of Alzheimer's disease: an integrated diagnostic model

    Xiao P, Wang Y, Li J et al. · Frontiers in neuroscience · 2026

  19. 0.75

    Enhancing brain age estimation with structural MRI and synthesized cerebral blood volume maps

    Jomsky J, Li Z, Igwe KC et al. · Brain communications · 2026

  20. 0.75

    Structural, Functional and Cognitive Validation of a Deep-Learning MCI-to-AD Conversion Model in OASIS-3

    Fin S, Moayedikia A · medRxiv : the preprint server for health sciences · 2026

  21. 0.75

    Plasma biomarker and machine learning modeling of clinical progression in cognitively normal individuals at risk for Alzheimer's disease

    Thabtah F, Kamalov F, Spencer R et al. · Neurodegenerative disease management · 2026

  22. 0.75

    Transcriptome-wide association analysis of Alzheimer's disease: construction and clinical validation of transcriptomic risk scores

    Zhang PF, Juan Z, Han J et al. · European archives of psychiatry and clinical neuroscience · 2026

  23. 0.75

    Discovering Heterogeneous Neurodegenerative Disease Patterns From MRI Data for Improved Prediction

    Zhang Y, Li H, Fan Y · Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention · 2027

  24. 0.72

    Clinical pathways matter for multimodal deep learning in early Alzheimer's disease detection

    Lu Y, Hammonds SK, Fernandez-Quilez A · Scientific reports · 2026

  25. 0.72

    A regularized semiparametric cure-rate model with high-dimensional imaging data

    Feng J, Nanshan M, Shi H et al. · Statistical methods in medical research · 2026

  26. 0.71

    Predicting future brain atrophy based on longitudinal MRI

    Hadji M, Moradi E, Tohka J · Journal of Alzheimer's disease : JAD · 2026

  27. 0.70

    SMaRT-Net: A novel framework of 7T brain MRI superresolution for Alzheimer's disease diagnosis and mild cognitive impairment prognostication

    Yoon D, Myong Y, Kim YG et al. · NeuroImage · 2026

  28. 0.70

    PatientSpace: A multimodal graph-based latent representation framework for modeling neurodegenerative disease heterogeneity

    Manouvriez D, Kuchcinski G, Lecerf S et al. · NeuroImage · 2026

  29. 0.70

    Separating ECog scale-score information from dyad availability: observation-process contributions to dyadic prediction of cognitive impairment in ADNI

    Cheng WKW · Research square · 2026

  30. 0.70

    Classification of tau status with machine learning models in amyloid-positive cohorts

    Lin YC, Chiu SC, Massey R et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  31. 0.67

    Elevated BrainAGE precedes cognitive impairment and improves prediction of future cognitive decline

    Moradi E, Dahnke R, Gaser C et al. · medRxiv : the preprint server for health sciences · 2026

  32. 0.67

    Quantifying generalization error in machine learning prediction of cognitive decline

    Huppi RM, Langer N, Hebling Vieira B · The journal of prevention of Alzheimer's disease · 2026

  33. 0.64

    Diagnostic classifications based on cognitive, CSF, and PET biomarkers across ADNI cohorts: cross-sectional and longitudinal variability

    Fotouhi M, Chui HC, Choupan J et al. · Brain communications · 2026

  34. 0.64

    NeuroOmics-Net: An interpretable multimodal deep learning framework for Alzheimer's disease diagnosis and progression prediction using neuroimaging, EEG, and genomic data

    Kavitha R, Premalatha K · Computers in biology and medicine · 2026

  35. 0.62

    Multi-dimensional attention framework for personalised Alzheimer's disease progression prediction across sporadic and genetic risk cohorts

    Song Z, Song S, Clare ICH et al. · Research square · 2026

  36. 0.61

    Data‑driven cognitive composites predict Abeta‑related decline and progression to MCI: the ADOPIC study

    Tallapragada B, Galna B, Shishegar R et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  37. 0.61

    EEG biomarkers can predict early-stage Alzheimer's disease and correlate with intracerebral pathology: a multimodal machine learning study

    Geng Z, Song W, Gao C et al. · Alzheimer's research & therapy · 2026

  38. 0.60

    Multi-threshold polygenic risk improves hippocampal-based cognitive decline prediction

    Janahi M, Lorenzini L, Oxtoby NP et al. · Genome medicine · 2026

  39. 0.58

    Investigating the amyloid-tau-neurodegeneration framework in Alzheimer's disease using semi-supervised multimodal imaging data fusion

    Cheng Y, Medina A, Korponay C et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2026

  40. 0.57

    Multivariate Random Forests for Cross-Modal Multi-Omics Integration

    Zhang W, Wang L, Franzmann EJ et al. · bioRxiv : the preprint server for biology · 2026

  41. 0.53

    Progressive loss of independence in neuronal representations predicts cognitive decline

    Sheets DEG, Ruff DA, Srinath R et al. · bioRxiv : the preprint server for biology · 2026

  42. 0.52

    Normative brain-state trajectories reveal deviation from healthy aging in AD

    Taimouri M, Ravindra V · bioRxiv : the preprint server for biology · 2026

04risk · older37편

  1. 0.93

    APOE epsilon4 Allele Dose and Time to Clinical Conversion from Mild Cognitive Impairment to Alzheimer's Disease Dementia: An ADNI Survival Analysis

    Khan FF, Kwon GR · Biomedicines · 2026

  2. 0.88

    Polypharmacy is associated with lower progression from MCI to Alzheimer's disease, with sex-specific patterns across drug classes

    Garcia-Zamora M, Pardo J, Esteve M et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2026

  3. 0.85

    Comparison of baseline characteristics between cognitively normal and mild cognitive impairment and association of white matter hyperintensity trajectories with diagnostic outcomes, cognition, and amyloid-beta protein: A longitudinal study

    Ba W, Bao C, Gong Y et al. · Journal of Alzheimer's disease : JAD · 2026

  4. 0.84

    Predicting progression from mild cognitive impairment to dementia with baseline neuropsychological test scores

    Kurniadi NE, Steele JS, Mattek N et al. · Journal of Alzheimer's disease : JAD · 2026

  5. 0.82

    Body mass index decline and cognitive trajectories in mild cognitive impairment: the role of maternal history of Alzheimer's disease

    Hernandez AP, Davila EG, Espinosa NR · Research square · 2026

  6. 0.82

    Trajectories and timing of accelerated decline in specific memory domains preceding Alzheimer's disease

    Long X, Rong M, Long S et al. · Frontiers in aging neuroscience · 2026

  7. 0.81

    Frontal Release Signs and Future Decline in Research Participants With Intact Cognition

    Bojarski LG, Jicha GA, Coskun EP et al. · JAMA network open · 2026

  8. 0.80

    The Cog-Aging: a 15-year cohort study of cognition in Brazilian older adults

    Engelmann GTO, de Alvarenga JC, Moro GCP et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  9. 0.80

    Diabetes mellitus accelerates preclinical Alzheimer's disease progression by amplifying the amyloid-to-tau pathway and attenuating brain-cognition resilience

    Jin H, Meng Y · Journal of Alzheimer's disease : JAD · 2026

  10. 0.80

    Error unawareness as a driver of cognitive decline in individuals at risk for Alzheimer's disease

    Andrade K, Lejeune FX, Houmani N et al. · Communications biology · 2026

  11. 0.78

    Baseline facial emotion recognition is associated with clinical decline across the Alzheimer's disease spectrum: a multi-instrument longitudinal assessment study

    Shim Y, Lim EY · Frontiers in aging neuroscience · 2026

  12. 0.78

    Comparison of Brain Age With Standard MRI Assessment for Dementia Risk Stratification in Subjective and Mild Cognitive Impairment

    De Vries S, Farkas K, Rhodius-Meester HFM et al. · Neurology · 2026

  13. 0.77

    Vision Impairment, Vision Correction, and Dementia Risk in Mild Cognitive Impairment

    Tang H, Wolk DA, Ying GS et al. · Journal of the American Geriatrics Society · 2026

  14. 0.72

    Prevalence of Lewy body pathology and phenotypic associations in patients with mild cognitive impairment: Evidence from the Interceptor study

    Baiardi S, Caldera S, Capellari S et al. · Alzheimer's & dementia (Amsterdam, Netherlands) · 2026

  15. 0.72

    Insulin resistance increases the risk of conversion to the subcortical small vessel type of dementia

    Axelsson Andren E, Kettunen P, Wallin A et al. · Cerebral circulation - cognition and behavior · 2026

  16. 0.69

    Depressive symptom instability predicts incident mild cognitive impairment and dementia in older adults

    Rutter LA, Hamilton LJ · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

  17. 0.68

    Predictive value of the Alzheimer polygenic risk score on cognitive decline in patients with mild cognitive impairment and Alzheimer's disease dementia

    Calm B, Hinojosa-Calleja A, Garcia-Gutierrez F et al. · The journal of prevention of Alzheimer's disease · 2026

  18. 0.67

    Head-to-head comparison of diffusion imaging markers for cognitive decline and risk of dementia: The population-based Rotterdam Study

    Rosbergen MT, Wolters FJ, Ikram MA et al. · Imaging neuroscience (Cambridge, Mass.) · 2026

  19. 0.66

    Midlife insulin resistance and brain beta-amyloid accumulation as predictors of change in late-life cognitive function - A 20-year follow-up study

    Pietila E, Karrasch M, Helin S et al. · Neurobiology of aging · 2026

  20. 0.66

    Cardiometabolic medication exposures and cognitive outcomes in Alzheimer's disease

    Wang Y, Goudey B, Masters CL et al. · Age and ageing · 2026

  21. 0.65

    Epigenetic Age and Resilience in the Framingham Heart Study

    Dacey R, Durape S, Wang M et al. · Neurology open access · 2026

  22. 0.64

    Edentulism and cognitive transitions: A multi-state analysis

    Tang L, Qiu C, Chi C et al. · Journal of Alzheimer's disease : JAD · 2026

  23. 0.59

    Microbiome functional gene pathways are indicative of cognitive performance in older adults at risk for Alzheimer's disease

    Zeamer AL, Lai Y, Loew E et al. · Gut microbes · 2026

  24. 0.59

    Subjective cognition trajectories, Alzheimer biomarkers, and incident mild cognitive impairment

    Kuhn E, Kleineidam L, Stark M et al. · The journal of prevention of Alzheimer's disease · 2026

  25. 0.59

    Comparator supplement patterns qualify the clinical interpretation of an EHR-derived glucosamine signal in Alzheimer's disease

    Nakashima S, Sato K, Niimi Y et al. · medRxiv : the preprint server for health sciences · 2026

  26. 0.58

    APOE4 moderates the association of sleep disturbance with cerebral amyloid burden but not with clinical conversion in cognitively normal older adults

    Lee MJ, Kim JH, Choi HJ et al. · Journal of Alzheimer's disease : JAD · 2026

  27. 0.58

    Dementia progression with GLP-1 receptor agonists in people with mild cognitive impairment and type 2 diabetes: target-trial emulation study

    Schechter M, Sehtman-Shachar DR, Fishkin A et al. · Alzheimer's & dementia (New York, N. Y.) · 2026

  28. 0.57

    Bidirectional transitions between subjective cognitive decline and normal cognition and risk of mild cognitive impairment: A multistate Markov model study in NACC UDS

    Xiao Y, Zhou Z, Jin M et al. · Journal of Alzheimer's disease : JAD · 2026

  29. 0.55

    The Joint Effects of Life's Essential 8 and Genetics on Mild Cognitive Impairment and Dementia Risk in People With Diabetes: Findings From the UK Biobank and All of Us

    Wu X, Zu Y, Lu Y et al. · Diabetes care · 2026

  30. 0.55

    Superoxide dismutase and glutathione interact to determine cognitive outcome among people with subjective cognitive decline (SCD): a prospective study

    Lin CH, Lane HY · European archives of psychiatry and clinical neuroscience · 2026

  31. 0.54

    Stages of objective memory impairment (SOMI) as a predictor of clinical progression in the A4 study

    Kumari P, Lipton RB, Aschenbrenner AJ et al. · The journal of prevention of Alzheimer's disease · 2026

  32. 0.53

    Is my loneliness killing me? Effects of loneliness and social isolation on transitions between cognitive status categories and death

    Yoneda T, Jackson KL, Noyer EC et al. · Journal of personality and social psychology · 2026

  33. 0.53

    Salivary Cortisol and Cognitive Decline and Alzheimer Disease in Older Adults

    Ng TKS, Beck T, Sudhini Y et al. · JAMA network open · 2026

  34. 0.53

    Longitudinal Trajectories of Cognitive Control and Theory of Mind in Amnestic and Non-Amnestic Mild Cognitive Impairment: Prospective Associations of Objective Sleep Duration

    Batzikosta A, Tsolaki M, Steiropoulos P et al. · Journal of clinical medicine · 2026

  35. 0.51

    Interaction Between COMT Genotype and MIND Diet, Cognitive Decline, and Incident Dementia: A Prospective Cohort Study

    Cornelis MC, van Dam RM, Bennett DA et al. · Nutrients · 2026

  36. 0.51

    Dietary Patterns and Cognitive Decline in Older Adults: Findings from the Western Australia Memory Study

    Blagojevic Castro C, Gardener SL, Jahan F et al. · Nutrients · 2026

  37. 0.50

    Incidence of dementia and mild cognitive impairment in two Indigenous Bolivian cohorts

    Gatz M, Mack WJ, Eid Rodriguez D et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

05trial · completed14편

  1. 0.95

    Recognition memory as a neuropsychological marker of progression in early-stage Alzheimer's disease: a 24-month prospective cohort study

    Russo MJ, Bueri J, Alba-Ferrara L et al. · Journal of clinical and experimental neuropsychology · 2026

  2. 0.90

    Cognitive dispersion in the Alzheimer's disease spectrum

    Marsault J, Vallet GT, Joubert S · Journal of the International Neuropsychological Society : JINS · 2026

  3. 0.89

    Prognostic value of Amyloid PET in Real-World Amnestic MCI: Influence of reader experience and interpretation method

    Echeveste B, Guillen EF, Prieto E et al. · European journal of nuclear medicine and molecular imaging · 2026

  4. 0.83

    Effects of language of test administration as a predictor of progression to Alzheimer's disease in bilingual Hispanic Americans: A pilot study

    Jagasia K, Li C · Applied neuropsychology. Adult · 2026

  5. 0.77

    Lost in Scheduling? A Reliable Tool for Detecting Subtle Cognitive Decline in Mild Cognitive Impairment and Mild Alzheimer's Disease

    Villain M, Beauchene D, Mevel-Becker M et al. · American journal of speech-language pathology · 2026

  6. 0.69

    Longitudinal CDR-Sum of Boxes trajectories in mild cognitive impairment reveal functional heterogeneity beyond cognitive decline: A latent class growth analysis

    Moon Y, Seo SW, Noh MY et al. · Journal of Alzheimer's disease : JAD · 2026

  7. 0.68

    Smartphone-based detection of subtle memory decline in prodromal Alzheimer's disease

    Polk SE, Clark LR, Basche K et al. · NPJ digital medicine · 2026

  8. 0.67

    Updating deficits in subjective cognitive decline: A differential pattern of executive dysfunction across clinical stages

    Wang Y, Zhan W, Wu Z et al. · International journal of clinical and health psychology : IJCHP · 2026

  9. 0.65

    Associations of Ginkgo biloba extract exposure with 12-month cognitive trajectories in amyloid PET-positive mild cognitive impairment and Alzheimer's disease: a pooled retrospective cohort study

    Yang Y, Kwak YT · BMC complementary medicine and therapies · 2026

  10. 0.65

    Pre-dementia clinical trajectories associated with neuronal alpha-synuclein neuropathologic change: a retrospective cohort study

    Vera-Campuzano E, Selma-Gonzalez J, Rodriguez-Baz I et al. · Research square · 2026

  11. 0.64

    Motor intrusion errors as a novel marker of neurodegeneration and executive dysfunction in Alzheimer's disease

    Keith CM, Phelps HE, Smith SR et al. · Neuropsychology · 2026

  12. 0.60

    Diagnostic Utility of Multi-Domain Language Measures Across the Alzheimer Disease Continuum

    Geng Z, Montembeault M, Coulombe V · medRxiv : the preprint server for health sciences · 2026

  13. 0.59

    Phase 2 Futility Trials in Alzheimer Disease and Mild Cognitive Impairment: A Cohort Analysis of the ADNI Data Set

    Ganesh A, Smith EE, Mostert J et al. · Neurology · 2026

  14. 0.50

    Reduced serum IL-6 as a potential peripheral marker of amnestic mild cognitive impairment: A pilot study

    Castro MM, Pavon RA, Moroni AD et al. · Medicina clinica · 2026

06systematic review · pubmed4편

  1. 0.83

    Anxiety Symptoms and Risk of Dementia Progression in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis

    Fresnais D, Fure B · Dementia and geriatric cognitive disorders · 2026

  2. 0.66

    Depression as a prognostic factor for conversion from mild cognitive impairment to all-cause dementia and Alzheimer's disease: a systematic review and meta-analysis of longitudinal studies

    Kassymzhanova M, Shonbay K, Shikhova OM et al. · Frontiers in public health · 2026

  3. 0.65

    Neuropsychiatric symptoms as predictors of progression to Alzheimer's disease in mild cognitive impairment: A comparative meta-analysis of apathy, depression, and anxiety

    Sun Y, Cao Y, Ma J et al. · International psychogeriatrics · 2026

  4. 0.54

    Peripheral immune markers in dementia: A systematic review and meta-analysis of risk, severity, and pathological correlates

    Toubasi AA, Al-Sayegh TN · Alzheimer's & dementia (New York, N. Y.) · 2026

07review · dysfunction1편

  1. 0.79

    Transcriptomic signatures as biomarkers for the progression of mild cognitive impairment

    Yang J, Li J, Mao L et al. · Frontiers in aging neuroscience · 2026